IOVS Advertisement
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1167/iovs.08-2521 on October 24, 2008
 (Investigative Ophthalmology and Visual Science. 2009;50:1329-1335.)
© 2009 by The Association for Research in Vision and Ophthalmology, Inc.
doi:10.1167/iovs.08-2521
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
iovs.08-2521v1
50/3/1329    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, J.
Right arrow Articles by Smith, L. E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, J.
Right arrow Articles by Smith, L. E. H.

Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative Retinopathy

Jing Chen, Kip M. Connor, Christopher M. Aderman, Keirnan L. Willett, Oskar P. Aspegren, and Lois E. H. Smith

From the Department of Ophthalmology, Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts.

PURPOSE. Erythropoietin (EPO), an oxygen-regulated hormone stimulating erythrocyte production, was recently found to be critical for retinal angiogenesis. EPO mRNA expression levels in retina are highly elevated during the hypoxia-induced proliferation phase of retinopathy. The authors investigated the inhibition of retinal EPO mRNA expression with RNA interference as a potential strategy to suppress retinal neovascularization and to prevent proliferative retinopathy.

METHODS. The authors used a mouse model of oxygen-induced retinopathy. Retinal EPO and Epo receptor (EpoR) expression during retinopathy development were quantified with real-time RT-PCR in whole retina and on laser-captured retinal vessels and neuronal layers. Retinal hypoxia was assessed with an oxygen-sensitive hypoxyprobe. A small interference RNA (siRNA) targeting EPO or control negative siRNA was injected intravitreally at postnatal (P) day 12, P14, and P15 during the hypoxic phase, and the effect on neovascularization was evaluated in retinal flatmounts at P17.

RESULTS. Retinal EPO mRNA expression in total retina was suppressed during the initial phase of vessel loss in retinopathy and was significantly elevated during the hypoxia-induced proliferative phase in all three neuronal layers in the retina, corresponding to an increased level of retinal hypoxia. EpoR mRNA expression levels also increased during the second neovascular phase, specifically in hypoxia-induced neovascular vessels. Intravitreous injection of EPO siRNA effectively inhibited approximately 60% of retinal EPO mRNA expression and significantly suppressed retinal neovascularization by approximately 40%.

CONCLUSIONS. Inhibiting EPO mRNA expression with siRNA is effective in suppressing retinal neovascularization, suggesting EPO siRNA is a potentially useful pharmaceutical intervention for treating proliferative retinopathy.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. Scheerer, N. Dunker, S. Imagawa, M. Yamamoto, N. Suzuki, and J. Fandrey
The anemia of the newborn induces erythropoietin expression in the developing mouse retina
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2010; 299(1): R111 - R118.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. Stahl, K. M. Connor, P. Sapieha, J. Chen, R. J. Dennison, N. M. Krah, M. R. Seaward, K. L. Willett, C. M. Aderman, K. I. Guerin, et al.
The Mouse Retina as an Angiogenesis Model
Invest. Ophthalmol. Vis. Sci., June 1, 2010; 51(6): 2813 - 2826.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. M. Vecchiarelli-Federico, D. Cervi, M. Haeri, Y. Li, A. Nagy, and Y. Ben-David
Vascular Endothelial Growth Factor--A Positive and Negative Regulator of Tumor Growth
Cancer Res., February 1, 2010; 70(3): 863 - 867.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Ohlmann, R. Seitz, B. Braunger, D. Seitz, M. R. Bosl, and E. R. Tamm
Norrin Promotes Vascular Regrowth after Oxygen-Induced Retinal Vessel Loss and Suppresses Retinopathy in Mice
J. Neurosci., January 6, 2010; 30(1): 183 - 193.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
S. Abhary, K. P. Burdon, R. J. Casson, M. Goggin, N. P. Petrovsky, and J. E. Craig
Association Between Erythropoietin Gene Polymorphisms and Diabetic Retinopathy
Arch Ophthalmol, January 1, 2010; 128(1): 102 - 106.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the Association for Research in Vision and Ophthalmology